Literature DB >> 8773185

In vitro effect of ciprofloxacin on HT-29 human colon carcinoma cell line: assessment of cell proliferation by thymidine uptake and silver nucleolar organizer regions (AgNOR) histomorphometry.

M Rabau1, A Nyska, D Dayan.   

Abstract

In an in vitro study, the effect of ciprofloxacin was examined on proliferation of HT-29 human colon carcinoma cell line. Cell proliferation was measured by 3H-thymidine uptake and silver nucleolar organizer region (AgNOR) histomorphometry. A significant increase in [3H]thymidine incorporation (p < 0.05) parallel with a significant increase in the mean AgNOR clusters/cells (p < 0.01) was noted after 5 days of cell exposure to ciprofloxacin. It is suggested that the assessment of AgNOR variables is useful in examination of quinolone effect on HT-29 human colon carcinoma cell proliferation.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8773185     DOI： 10.1007/bf02733673

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN： 0340-5761            Impact factor:   5.153


  21 in total

1.  Improvement in the staining and in the visualization of the argyrophilic proteins of the nucleolar organizer region at the optical level.

Authors:  D Ploton; M Menager; P Jeannesson; G Himber; F Pigeon; J J Adnet
Journal:  Histochem J       Date:  1986-01

2.  Correlation of Ag-NOR protein measurements with prognosis in canine transmissible venereal tumour.

Authors:  A Harmelin; A Zuckerman; A Nyska
Journal:  J Comp Pathol       Date:  1995-05       Impact factor: 1.311

3.  Influence of ofloxacin, norfloxacin, nalidixic acid, pyromidic acid and pipemidic acid on human gamma-interferon production and blastogenesis.

Authors:  C De Simone; L Baldinelli; M Ferrazzi; S De Santis; L Pugnaloni; F Sorice
Journal:  J Antimicrob Chemother       Date:  1986-06       Impact factor: 5.790

4.  Nucleolar organiser region (NOR) distribution as a diagnostic marker in oral keratosis, dysplasia and squamous cell carcinoma.

Authors:  K A Warnakulasuriya; N W Johnson
Journal:  J Oral Pathol Med       Date:  1993-02       Impact factor: 4.253

5.  Variations in the occurrence of silver-staining nucleolar organizer regions (AgNORs) in non-proliferating and proliferating tissues.

Authors:  R D Leek; M R Alison; C E Sarraf
Journal:  J Pathol       Date:  1991-09       Impact factor: 7.996

6.  4-Quinolone antibiotics: positive genotoxic screening tests despite an apparent lack of mutation induction.

Authors:  A Bredberg; M Brant; K Riesbeck; Y Azou; A Forsgren
Journal:  Mutat Res       Date:  1989-03       Impact factor: 2.433

7.  4-Quinolone drugs affect cell cycle progression and function of human lymphocytes in vitro.

Authors:  A Forsgren; S F Schlossman; T F Tedder
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191

8.  Quinolones affect thymidine incorporation into the DNA of human lymphocytes.

Authors:  A Forsgren; A K Bergh; M Brandt; G Hansson
Journal:  Antimicrob Agents Chemother       Date:  1986-03       Impact factor: 5.191

9.  Prognosis of canine mast cell tumors: a comparison of three methods.

Authors:  J P Simoes; P Schoning; M Butine
Journal:  Vet Pathol       Date:  1994-11       Impact factor: 2.221

Review 10.  Nucleolar organiser regions in pathology.

Authors:  M J Egan; J Crocker
Journal:  Br J Cancer       Date:  1992-01       Impact factor: 7.640
View more
  2 in total

1.  Ciprofloxacin decreases survival in HT-29 cells via the induction of TGF-beta1 secretion and enhances the anti-proliferative effect of 5-fluorouracil.

Authors:  Leonidas A Bourikas; George Kolios; Vassilis Valatas; George Notas; Ioannis Drygiannakis; Iordanis Pelagiadis; Pinelopi Manousou; Stefanos Klironomos; Ioannis A Mouzas; Elias Kouroumalis
Journal:  Br J Pharmacol       Date:  2009-04-09       Impact factor: 8.739

2.  Effect of Ciprofloxacin on Susceptibility to Aortic Dissection and Rupture in Mice.

Authors:  Scott A LeMaire; Lin Zhang; Wei Luo; Pingping Ren; Alon R Azares; Yidan Wang; Chen Zhang; Joseph S Coselli; Ying H Shen
Journal:  JAMA Surg       Date:  2018-09-19       Impact factor: 14.766
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.